An interventional study of Breastfeeding clinical practice guideline (CPG) for congenital heart disease (CHD) in Congenital Heart Disease (CHD), sponsored by Carelon Research. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Carelon Research · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Heart Defects, Congenital by Carelon Research — 2 open to participants now, 4 under way, 1 of them phase 3. Heart Defects, Congenital · Carelon Research.
Among the 10 studies in Heart Defects, Congenital by Carelon Research, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 9th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →2 of the 10 studies in Heart Defects, Congenital by Carelon Research are open now, in 1 country. Recruiting first, the newest first:
Carelon Research · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 1
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 266 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 177 across the 8 interventional studies, 410 across the 2 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Carelon Research is the lead sponsor of 59 studies on the registry; 4 are open to participants now.
1 of the studies in Heart Defects, Congenital by Carelon Research that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05268094Carelon ResearchComparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial) | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Heart Defects, Congenital by Carelon Research, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to enhance the rates of direct breast feeding (DBF) among infants with congenital heart disease (CHD), and to gain insights into the implications of DBF on key metrics of child and parent well-being. A multicenter parallel cluster platform design will be employed. The intervention will be a multifaceted approach to enhance direct breastfeeding. Participating sites will be randomized into either intervention (strategies to enhance direct breastfeeding) or conventional care.
This is a domain of the Building Optimal Strategies to Enhance Parent and Infant Wellbeing in CHD (BOND) platform trail. BOND is a randomized, multifactorial, adaptive platform trial that seeks to optimize parent wellbeing and infant development following prenatal or neonatal diagnosis of congenital heart disease (CHD). The aim is to increase the proportion of infants with critical CHD who received direct breastfeeding at four months of age and to determine the impact of direct breastfeeding on maternal and infant health. Infants with congenital heart disease have lower rates of breastfeeding than the healthy population. Direct breastfeeding may be particularly beneficial in this population to reduce medical complications. In addition, direct breastfeeding may benefit maternal child bonding and enhance maternal mental health. Follow-up will continue through 12 months of infant age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Both mothers and infants are study participants.
Inclusion criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The clinical practice guideline (CPG) intervention will be developed by the clinical centers randomized to this arm. The intervention plan will likely include: 1) prenatal counseling; 2) viewing a video on breastfeeding CHD infants; 3) individual counseling by a registered lactation consultant (RLC), 4) weekly personal contact in-hospital by the RLC, 5) frequent contact post discharge by the RLC through the first year or until breastfeeding is discontinued, 6) provision of high-quality breast pumps, 7) incentive to continue with pumping breastmilk or direct breastfeeding.
Other: Breastfeeding clinical practice guideline (CPG) for congenital heart disease (CHD)
This arm will receive standard of care with respect to breastfeeding at the clinical centers randomized to this group.
The clinical practice guideline (CPG) intervention will be developed by the clinical centers randomized to this arm. The intervention plan will likely include: 1) prenatal counseling; 2) viewing a video on breastfeeding CHD infants; 3) individual counseling by a registered lactation consultant (RLC), 4) weekly personal contact in-hospital by the RLC, 5) frequent contact post discharge by the RLC through the first year or until breastfeeding is discontinued, 6) provision of high-quality breast pumps, 7) incentive to continue with pumping breastmilk or direct breastfeeding.
direct breastfeeding at 4 months
any direct breastfeeding (yes/no)
Time frame: 4 months
direct breastfeeding at 4 months in subpopulation of African Americans
any direct breastfeeding (yes/no) in subpopulation of African Americans
Time frame: 4 months
Difference in Parental Stress Scale™ (PSS) from baseline to 4 months
The Parental Stress Scale™ (PSS) is a measure of parental stress. The total score can range from 18 to 90, with higher scores indicating greater levels of parental stress and lower scores reflecting higher satisfaction with parenting.
Time frame: baseline to 4 months
Difference in Mother-Infant Bonding Scale (MIBS) from baseline to 4 months
The Mother-Infant Bonding Scale (MIBS) is a measure of mother-infant bonding. The score ranges from 0-24, with higher scores indicating more significant bonding challenges
Time frame: baseline to 4 months
Weight for age Z-score < -3 at 4 months
WHO weight for age Z-score \< -3
Time frame: 4 months
Freedom from necrotizing enterocolitis (NEC) through 4 months of age
necrotizing enterocolitis
Time frame: 4 months
Freedom from infection through 4 months of age
freedom from infection requiring hospital administration of antimicrobials for more than 48 hours
Time frame: 4 months
Freedom from other major medical complications through 4 months of age
freedom from other major medical complications through 4 months of age
Time frame: baseline to 4 months
Dysbiotic gut microbiome at 4 months of age
Dysbiotic index measured from gut microbiome
Time frame: 4 months
Plan to share: Yes — De-identified public use datasets with all study data will be created in accordance with NIH policy
Supporting information: Study protocol
Time frame: Data will be shared as soon as possible, but no later than the time of an associated publication or the end of the grant period, whichever comes first. Data will be available for as long as it is deemed useful for the larger research community, as directed by the PHN NHLBI project officers.
Access criteria: Creation of (free) login on PHN public website
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jun 2029, 35 months after the start.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 35 months is close to that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carelon Research